On Monday, Immunome Inc (NASDAQ: IMNM) was 3.22% up from the session before settling in for the closing price of $10.87. A 52-week range for IMNM has been $8.97 – $30.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 17.82%. With a float of $69.73 million, this company’s outstanding shares have now reached $84.67 million.
Considering the fact that the conglomerate employs 55 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.
Immunome Inc (IMNM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 17.66%, while institutional ownership is 64.99%. The most recent insider transaction that took place on Jan 31 ’25, was worth 1,162,500. In this transaction President and CEO of this company bought 150,000 shares at a rate of $7.75, taking the stock ownership to the 669,636 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President and CEO bought 66,057 for $9.54, making the entire transaction worth $630,263. This insider now owns 485,693 shares in total.
Immunome Inc (IMNM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 17.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.01% during the next five years compared to -48.48% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 93.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -3.09 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Compared to the last year’s volume of 1.05 million, its volume of 1.27 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 65.39%. Additionally, its Average True Range was 0.86.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 29.68%, which indicates a significant decrease from 63.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.18% in the past 14 days, which was higher than the 73.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.36, while its 200-day Moving Average is $13.07. Nevertheless, the first resistance level for the watch stands at $12.17 in the near term. At $13.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.79. If the price goes on to break the first support level at $10.55, it is likely to go to the next support level at $9.87. Should the price break the second support level, the third support level stands at $8.93.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are 79,777K outstanding shares of the company, which has a market capitalization of 950.05 million. As of now, sales total 14,020 K while income totals -106,810 K. Its latest quarter income was 2,910 K while its last quarter net income were -47,100 K.
